Table 3 of
Nieto-Miguel, Mol Vis 2011; 17:2102-2117. Table 3 of
Nieto-Miguel, Mol Vis 2011; 17:2102-2117.
Table 3. Ingenuity canonical pathways that were most significantly affected.
| Ingenuity Canonical Pathways | -Log(B-H P-value)* | Ratio | Molecules |
|---|---|---|---|
| Wnt/β2-catenin Signaling | 8.54E+00 | 6.67E-02 | SOX2, CDH2, GJA1, AXIN1, FRAT1, DVL1, BTRC, FZD1, CCND1, WNT1, APC |
| Notch Signaling | 3.28E+00 | 9.76E-02 | NOTCH2, DLL1, DTX1, JAG1 |
| Cell Cycle: G1/S Checkpoint Regulation | 2.58E+00 | 6.78E-02 | CCNE1, HDAC2, BTRC, CCND1 |
| Actin Cytoskeleton Signaling | 1.49E+00 | 2.20E-02 | FGF4, CDC42, ACTC1, APC, FGF1 |
| Aryl Hydrocarbon Receptor Signaling | 1.34E+00 | 2.58E-02 | CCNA2, CCNE1, ALDH1A1, CCND1 |
| Clathrin-mediated Endocytosis | 1.34E+00 | 2.42E-02 | FGF4, CDC42, ACTC1, FGF1 |
| Axonal Guidance Signaling | 1.34E+00 | 1.52E-02 | CDC42, BMP2, FZD1, WNT1, BMP1 |
| FGF Signaling | 1.27E+00 | 3.49E-02 | FGF4, FGFR1, FGF1 |
| Ephrin Receptor Signaling | 1.27E+00 | 2.07E-02 | CDC42, AXIN1, CXCL12, FGF1 |
| T Cell Receptor Signaling | 1.11E+00 | 2.78E-02 | CD8A, CD3D, CD8B |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 1.07E+00 | 4.65E-02 | BTRC, CDC2 |
| Tight Junction Signaling | 8.86E-01 | 1.83E-02 | CDC42, ACTC1, PARD6A |
| NF-Κ°B Signaling | 8.86E-01 | 2.08E-02 | HDAC2, BMP2, BTRC |
| Calcium-induced T Lymphocyte Apoptosis | 8.21E-01 | 3.28E-02 | HDAC2, CD3D |
| Leukocyte Extravasation Signaling | 7.08E-01 | 1.55E-02 | CDC42, CXCL12, ACTC1 |
| BMP signaling pathway | 7.08E-01 | 2.50E-02 | BMP2, BMP1 |
| Regulation of Actin-based Motility by Rho | 7.08E-01 | 2.17E-02 | CDC42, ACTC1 |
| PTEN Signaling | 6.12E-01 | 2.02E-02 | CDC42, CCND1 |
| Fcγ3 Receptor-mediated Phagocytosis in Macrophages and Monocytes | 5.94E-01 | 1.92E-02 | CDC42, ACTC1 |
| CD28 Signaling in T Helper Cells | 4.92E-01 | 1.65E-02 | CDC42, CD3D |
| Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells | 4.92E-01 | 3.85E-02 | CD3D |
| Glucocorticoid Receptor Signaling | 4.92E-01 | 1.09E-02 | HSPA9, BGLAP, CD3D |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 4.73E-01 | 1.48E-02 | FGFR1, FGF1 |
| Sonic Hedgehog Signaling | 4.34E-01 | 3.23E-02 | CDC2 |
| Ascorbate and Aldarate Metabolism | 4.12E-01 | 1.22E-02 | ALDH1A1 |
| Calcium Signaling | 3.39E-01 | 9.71E-03 | HDAC2, ACTC1 |
| Retinol Metabolism | 3.39E-01 | 1.56E-02 | ALDH1A1 |
| Integrin Signaling | 3.39E-01 | 1.01E-02 | CDC42, ACTC1 |
| Huntington’s Disease Signaling | 3.39E-01 | 8.62E-03 | HDAC2, HSPA9 |
| Histidine Metabolism | 3.39E-01 | 9.01E-03 | ALDH1A1 |
| GM-CSF Signaling | 3.39E-01 | 1.54E-02 | CCND1 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 3.39E-01 | 1.37E-02 | ADAR |
| Macropinocytosis | 3.39E-01 | 1.43E-02 | CDC42 |
| CCR5 Signaling in Macrophages | 3.39E-01 | 1.16E-02 | CD3D |
| Neurotrophin/TRK Signaling | 3.39E-01 | 1.32E-02 | CDC42 |
| Caveolar-mediated Endocytosis | 3.39E-01 | 1.25E-02 | ACTC1 |
| PXR/RXR Activation | 3.39E-01 | 1.16E-02 | ALDH1A1 |
| LPS-stimulated MAPK Signaling | 3.39E-01 | 1.27E-02 | CDC42 |
| Bile Acid Biosynthesis | 3.39E-01 | 1.03E-02 | ALDH1A1 |
| Chemokine Signaling | 3.39E-01 | 1.30E-02 | CXCL12 |
| L2-alanine Metabolism | 3.39E-01 | 1.01E-02 | ALDH1A1 |
| VDR/RXR Activation | 3.39E-01 | 1.25E-02 | BGLAP |
| Butanoate Metabolism | 3.39E-01 | 7.75E-03 | ALDH1A1 |
| Pyruvate Metabolism | 3.39E-01 | 6.90E-03 | ALDH1A1 |
| CTLA4 Signaling in Cytotoxic T Lymphocytes | 3.39E-01 | 1.16E-02 | CD3D |
| TGF-β2 Signaling | 3.39E-01 | 1.16E-02 | BMP2 |
| Lysine Degradation | 3.39E-01 | 6.94E-03 | ALDH1A1 |
| Propanoate Metabolism | 3.39E-01 | 7.94E-03 | ALDH1A1 |
| Apoptosis Signaling | 3.39E-01 | 1.06E-02 | CDC2 |
| p53 Signaling | 3.39E-01 | 1.15E-02 | CCND1 |
| VEGF Signaling | 3.39E-01 | 1.05E-02 | ACTC1 |
| SAPK/JNK Signaling | 3.39E-01 | 1.08E-02 | CDC42 |
| Glycerolipid Metabolism | 3.39E-01 | 6.90E-03 | ALDH1A1 |
| Valine, Leucine and Isoleucine Degradation | 3.39E-01 | 9.35E-03 | ALDH1A1 |
| FXR/RXR Activation | 3.39E-01 | 1.00E-02 | FOXA2 |
| Glycolysis/Gluconeogenesis | 3.33E-01 | 7.09E-03 | ALDH1A1 |
| Nicotinate and Nicotinamide Metabolism | 3.33E-01 | 7.75E-03 | CDC2 |
| fMLP Signaling in Neutrophils | 3.03E-01 | 8.00E-03 | CDC42 |
| Arginine and Proline Metabolism | 3.01E-01 | 5.62E-03 | ALDH1A1 |
| PI3K/AKT Signaling | 3.00E-01 | 7.41E-03 | CCND1 |
| Protein Ubiquitination Pathway | 2.60E-01 | 4.95E-03 | BTRC |
| Inositol Phosphate Metabolism | 2.60E-01 | 5.78E-03 | CDC2 |
| B Cell Receptor Signaling | 2.54E-01 | 6.54E-03 | CDC42 |
| CXCR4 Signaling | 2.51E-01 | 6.10E-03 | CXCL12 |
| IL-8 Signaling | 2.51E-01 | 5.46E-03 | CCND1 |
| Tryptophan Metabolism | 2.51E-01 | 4.20E-03 | ALDH1A1 |
| RAR Activation | 2.51E-01 | 5.49E-03 | ALDH1A1 |
| Role of NFAT in Regulation of the Immune Response | 2.51E-01 | 5.38E-03 | CD3D |
| Fatty Acid Metabolism | 2.51E-01 | 5.29E-03 | ALDH1A1 |
| NRF2-mediated Oxidative Stress Response | 2.51E-01 | 5.46E-03 | ACTC1 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 2.29E-01 | 5.05E-03 | ALDH1A1 |